Loading…

Loading grant details…

Active HORIZON European Commission

CAR T cells Rewired to prevent EXhaustion in the tumour microenvironment

€2.73M EUR

Funder European Commission
Recipient Organization Stemmatters, Biotecnologia E Mediciina Regenerativa Sa
Country Portugal
Start Date Apr 01, 2023
End Date Jun 30, 2027
Duration 1,551 days
Number of Grantees 6
Roles Associated Partner; Participant; Coordinator
Data Source European Commission
Grant ID 101099867
Grant Description

Although immunotherapy of select hematological malignancies using Chimeric Antigen Receptor (CAR) redirected T lymphocytes has recently gained regulatory approval, successful treatment of solid tumors using CAR T cells remains elusive. One salient problem is the limited efficacy and untimely exhaustion of CAR T cells in the tumor microenvironment (TME).

Combining innovative methods of genome editing, chemistry and immunology, CAR T-REX proposes to explore a novel concept of building auto-regulated genetic circuits into CAR T cells to selectively circumvent their exhaustion upon activation in the TME.

Genetic rewiring will be achieved by precisely inserting artificial miRNAs under endogenous exhaustion-related Driver promoters to downregulate Target genes that cause exhaustion. Proprietary technology enables specific replacement of the Driver gene without risking off-target mutations.

Further advantages of combined insertion and silencing are (i) the ability to regulate when a gene is turned on/off by biologically and clinically relevant cellular cues, and (ii) multiple gene-knockdown with a single dsDNA cleavage and RNA-silencing of both alleles.

These genetic modifications will be implemented using a novel high-performance peptide-based gene delivery platform with unlimited loading capacity, allowing combination of several types of cargo, as well as economical large scale GMP production.

Rewired HER2/Neu (ErbB2) redirected CAR T cells will be tested on preclinical breast and gastric carcinomas, and variants that eliminate tumors resistant to conventional 2nd and 3rd generation peers (without adverse events) will be developed/manufactured following quality-by-design principles under GMP-like conditions, thus accelerating the pathway towards clinical translation.

These approaches will also constitute a proof-of-concept for modifying therapeutic cell products, with the potential to considerably improve their safety, specificity, efficacy, scalability and cost.

All Grantees

Debreceni Egyetem; Universidad de Santiago de Compostela; Stemmatters, Biotecnologia E Mediciina Regenerativa Sa; Targetgene Biotechnologies Ltd; Stiftung Leibniz-Institut Fur Immuntherapie

Advertisement
Apply for grants with GrantFunds
Advertisement
Browse Grants on GrantFunds
Interested in applying for this grant?

Complete our application form to express your interest and we'll guide you through the process.

Apply for This Grant